Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nicolas Maxymiv

Anesthesiology Richmond, VA Doctor of Osteopathy

NPI 1487074654 CMS profile 7226708

1250 E. Marshall St., Box 980459, Richmond, VA 23298

Open in the dashboard

General payments

$8,579

74 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nicolas Maxymiv of Richmond, VA is reported in the CMS Open Payments database as having received $8,579 across 74 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Anesthesiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $254 2
2024 General $1,114 8
2023 General $202 2
2022 General $402 3
2021 General $717 20
2020 General $405 5
2019 General $5,485 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nicolas Maxymiv
  • Anesthesiology median
  • Middle half of Anesthesiology
  • National median

In program year 2025, general payments to Nicolas Maxymiv were reported at $254. Among 18,548 Anesthesiology profiles paid that year, the median was $58 and the middle half received between $26 and $153.

Show as a table
Year Nicolas Maxymiv Anesthesiology median Middle half National median
2019 $5,485 $72 $23–$151 $163
2020 $405 $36 $17–$120 $114
2021 $717 $49 $21–$135 $132
2022 $402 $52 $22–$144 $149
2023 $202 $53 $23–$143 $160
2024 $1,114 $55 $25–$150 $164
2025 $254 $58 $26–$153 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic USA, Inc. $4,171 20 payments
  2. Boston Scientific Corporation $1,775 18 payments
  3. Abbott Laboratories $1,361 13 payments
  4. Medtronic, Inc. $622 11 payments
  5. Stryker Corporation $161 1 payment
  6. Bioventus LLC $134 1 payment
  7. COMSORT, Inc $100 1 payment
  8. Relievant Medsystems, Inc. $94 1 payment
  9. Merz North America, Inc. $41 1 payment
  10. Ipsen Biopharmaceuticals, Inc $24 1 payment
  11. Other $95 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $3,335 14 payments
  2. Food and Beverage $3,144 57 payments
  3. Grant $2,000 2 payments
  4. Consulting Fee $100 1 payment
Products named General payments · program years 2019–2025
  1. SYNCHROMED $2,000 2 payments
  2. Proclaim Family of SCS IPGs $1,353 12 payments
  3. KYPHON Balloon Kyphoplasty $1,315 6 payments
  4. INTELLIS Spinal Cord Neurostimulation $713 9 payments
  5. Intracept $604 3 payments
  6. OSTEOCOOL RF ABLATION SYSTEM $209 2 payments
  7. INTELLIS Spinal Cord Neurostimulation $195 5 payments
  8. GENERAL - PAIN MANAGEMENT $163 6 payments
  9. IVS - IVAS $161 1 payment
  10. INTELLIS ADAPTIVESTIM $154 1 payment
  11. Other $1,428 25 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

1,794

Median for Anesthesiology: 322

Drug cost

$69,641

Median for Anesthesiology: $8,738

Branded share of claims

12.8%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Buprenorphine Generic 105 $34,818
Belbuca Buprenorphine Hcl Brand 22 $9,395
Pregabalin Generic 242 $6,450
Lidocaine Generic 32 $4,256
Gabapentin Generic 268 $3,075
Duloxetine Hcl Generic 215 $3,061
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 142 $1,922
Tizanidine Hcl Generic 142 $1,340
Methocarbamol Generic 100 $840
Acetaminophen-Codeine Acetaminophen With Codeine Brand 22 $644

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$106,949

Medicare's payments for the services billed

Medicare patients

388

Average age 73

Services billed

1,594

242 women, 146 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 36%
Diabetes 33%
Ischemic heart disease 32%
Osteoporosis 29%
Chronic kidney disease 28%
Heart failure 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

74 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Anesthesiology in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record